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Abstract
Background
Erythema nodosum leprosum (ENL) is a systemic inflammatory complication occurring
mainly in patients with lepromatous leprosy (LL) and borderline lepromatous leprosy (BL).
Prednisolone is widely used for treatment of ENL reactions. However, it has been reported
that prolonged treatment with prednisolone increases the risk for prednisolone-induced
complications such as osteoporosis, diabetes, cataract and arteriosclerosis. It has been
speculated that perhaps these complications result from lipid profile alterations by predniso-
lone. The effects of extended prednisolone treatment on lipid profiles in ENL patients have
not been studied in leprosy patients with ENL reactions. Therefore, in this study we con-
ducted a case-control study to investigate the changes in lipid profiles and serological
responses in Ethiopian patients with ENL reaction after prednisolone treatment.
Methods
A prospective matched case–control study was employed to recruit 30 patients with ENL
and 30 non-reactional LL patient controls at ALERT Hospital, Ethiopia. Blood samples were
obtained from each patient with ENL reaction before and after prednisolone treatment as
well as from LL controls. The serological host responses to PGL-1, LAM and Ag85 M. leprae
antigens were measured by ELISA. Total cholesterol (TC), triglyceride (TG), high density
lipoprotein (HDL) and low density lipoprotein (LDL) were measured by spectrophotometric
method.
Results
The host antibody response to M. leprae PGL-1, LAM and Ag85 antigens were significantly
reduced in patients with ENL reactions compared to LL controls after treatment. Comparison
between patients with acute and chronic ENL showed that host-response to PGL-1 was
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significantly reduced in chronic ENL after prednisolone treatment. Untreated patients with
ENL reactions had low lipid concentration compared to LL controls. However, after treat-
ment, both groups had comparable lipid profiles except for LDL, which was significantly
higher in patients with ENL reaction. Comparison within the ENL group before and after
treatment showed that prednisolone significantly increased LDL and HDL levels in ENL
patients and this was more prominent in chronic ENL than in acute patients with ENL.
Conclusion
The significantly increased prednisolone-induced LDL and TG levels, particularly in patients
with chronic ENL reactions, is a concern in the use of prednisolone for extended periods in
ENL patients. The findings highlight the importance of monitoring lipid profiles during treat-
ment of patients to minimize the long-term risk of prednisolone-induced complications.
Author summary
Erythema Nodosum Leprosum (ENL) reaction is a severe multisystem immune-mediated
complication of lepromatous and borderline leprosy. It causes high morbidity and mortal-
ity and usually requires urgent medical attention. Although thalidomide is an effective
drug for ENL treatment, it is not available in many leprosy endemic countries including
Ethiopia. Prednisolone is widely used for treatment of ENL reactions but its efficacy is less
than 40%. As a result, patients with ENL reactions receive Prednisolone for prolonged
periods. However, it has been reported that prolonged treatment with prednisolone
increases the risk for prednisolone-induced complications such as osteoporosis, diabetes,
cataract and arteriosclerosis. It has been hypothesized that perhaps these complications
result from changes in lipid concentration due to prednisolone. Therefore, this study was
aimed to determine changes in lipid profiles in patients with ENL reactions. We found
that prednisolone treatment not only alters lipid concentrations in patients with ENL
reactions but also reduced the antibody responses to M. leprae antigens. Our result has
shown that prednisolone treatment has increased low and high lipoproteins in patients
with ENL reactions. We also found that use of prednisolone for prolonged time in chronic
ENL was correlated with increased triglycerides (TG) and low density lipoproteins (LDL)
showing the need for monitoring lipid profiles during prednisolone treatment of these
patients to avoid the risks associated with increased TG and HDL such as diabetes and
hypertension.
Introduction
Leprosy is a disease caused by Mycobacterium leprae which mainly affects the skin and the
peripheral nerves[1]. Depending on the host immune response, the disease manifests with a
spectrum of five relatively distinct clinical pictures: localized tuberculoid leprosy (TT), three
forms of borderline leprosy (BT, BB, BL) and the generalized lepromatous leprosy (LL) based
on the Ridley-Jopling (RJ) classification [2]. In addition to the five clinical forms, most leprosy
patients develop reactions called type-1 and type-2 leprosy reactions [3]. Leprosy reactions are
immune-mediated incidents of acute or sub-acute inflammation and are the main complica-
tions of the disease leading to permanent disability. Type-2 or Erythema Nodosum Leprosum
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reaction (ENL) is an immune-mediated inflammatory complication, occurring in about 50%
of LL and 10% of borderline lepromatous leprosy (BL) patients[4, 5]. ENL occurs as an acute
episode but can develop into a chronic phase or can be recurrent [6]. It involves multiple
organs and manifests as a systemic illness [7]. The occurrence of crops of tender erythematous
skin lesions is the clinical diagnostic feature of ENL[8]. Accurate laboratory confirmation for
ENL is not yet available. Potential biomarkers related to inflammatory cytokines such as TNF-
α [9], reduced regulatory T-cells[10], increased levels of neutrophils infiltration [11], mycobac-
terial cell-wall and protein antigens [12] have been investigated.
Identification and characterization of M. leprae specific antigens for accurate and reliable
diagnosis of leprosy and leprosy reactions is a major priority in leprosy research. Phenolic gly-
colipid-1 (PGL-1) is a surface glycolipid in M. leprae which is believed to interact with the host
immune cells [13]. PGL-I has been implicated in the tropism of M. leprae for Schwann cells,
through specific binding to laminin, and is reported to play an important role in down-regula-
tion of the inflammatory immune response and inhibition of dendritic cell maturation and
activation, thereby facilitating the persistence of M. leprae [14].
ENL is treated with prednisolone or with thalidomide. Thalidomide is not imported in
most leprosy endemic countries such as Ethiopia and is restricted due to its potential for birth
defects in humans when taken during pregnancy. Prednisolone is an immunosuppressive drug
used for the treatment of chronic inflammatory diseases. In the majority of patients, ENL is a
chronic condition requiring prolonged immunosuppression [15]. Although the adverse effects
of prednisolone treatment in patients with ENL has not been well studied, one study has
reported significant mortality and morbidity associated with prolonged administration of
prednisolone in patients with chronic ENL in Ethiopia [15]. A meta- analysis study reported
that prolonged treatment with prednisolone increases the risk for osteoporosis and fracture,
thinning and bruising of the skin, risk of developing cataracts and arthrosclerosis [16].
Steroid induced diabetes is increasingly frequent in patients receiving prolonged steroid
treatment [17]. Among 20 patients with ENL reaction who had received prednisolone treat-
ment in a recent study, 5 (25%) were reported to have developed diabetes mellitus while 7
(35%) developed hypertension ([17]. Similarly, a significant proportion (23.5%) of leprosy
patients treated with prednisolone for reactions developed steroid induced diabetes mellitus in
India [18]. Several studies suggest that the adverse effects of prednisolone could result from
altered lipid profiles in patients with inflammatory diseases [16–18]. In patients with adrenal
insufficiency, prednisolone increased LDL levels significantly and is a recognized risk factor
for cardiovascular disease in these patients ([19]. Similar effects have also been reported in
Rheumatoid Arthritis [20] and Systemic Lupus Erythematosus [21].
However, the effects of prolonged (months to several years) prednisolone treatment on
lipid profiles in patients with ENL reactions have not been investigated although all Ethiopian
leprosy patients with ENL reactions are being treated with prednisolone. We conducted a
case-control follow-up study to investigate the changes in lipid profiles and evaluate the sero-
logical responses in patients with ENL reactions after prednisolone treatment. We also investi-
gated the changes in lipid profiles in patients with acute and chronic ENL.
Materials and methods
Ethics statement
The study was reviewed and approved by the AHRI/ALERT Ethics review committee, (P032/
12) and the National Research Ethics Review Committee, Ethiopia (#310/450/06) as well as by
the Institutional Ethical Committee of the London School of Hygiene and Tropical Medicine,
UK, (#6391). Written informed consent was obtained from all study participants before
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enrolment. Children under 18 years were excluded from the study. All personal information
was kept confidential and data was analysed anonymously.
Study design and sample size determination
A prospective matched case-control study with follow-up after the initiation of prednisolone
treatment was used to recruit 30 untreated patients with ENL reactions (i.e. patients newly pre-
senting with reactions who have not yet received prednisolone treatment) and 30 non-reac-
tional LL patient controls between December 2014 and January 2016 at ALERT Hospital,
Ethiopia. Sample size was calculated assuming a constant probability of exposure thorough the
pool of controls. Sample size was obtained by using the G� power 3.1.7 software with the input
parameters: α = 0.05, power (β) = 0.8.
Patient recruitment and blood sample collection
All patients recruited into this study were attending the ALERT Hospital, Addis Ababa, Ethio-
pia. All study patients were recruited to the study between December 2014 and January 2016.
The patients were classified clinically on the leprosy spectrum based on the Ridley-Jopling
(RG) classification schemes[2]. ENL was clinically diagnosed when a patient with BL or LL lep-
rosy had painful crops of tender cutaneous erythematous skin lesions and systemic features of
disease often fever, neuritis and bone pain with or without other accompanying clinical symp-
toms such as neuritis, joint pain, bone tenderness, orchitis, iritis, oedema malaise, anorexia
and lymphadenopathy [5]. New ENL was defined as the occurrence of ENL for the first time in
a patient with LL or BL. The nature of ENL was defined as acute for a single episode lasting
less than 24 weeks while on corticosteroids treatment, recurrent if a patient experienced a sec-
ond or subsequent episode of ENL occurring 28 days or more after stopping treatment for
ENL and chronic if occurring for 24 weeks or more during which a patient required ENL treat-
ment either continuously or where any treatment free period had been 27 days or less [8, 15].
Lepromatous leprosy was clinically diagnosed when a patient had widely disseminated nodular
lesions with ill-defined borders and bacterial index (BI) above 2 [8, 15]. Patients were recruited
prospectively. Patients with other leprosy clinical spectrum such as tubeculoid (TT), border-
lines and type 1 reactions were excluded from the study. Pregnant and lactating mothers, anae-
mic patients, patients with concomitant sever conditions such as TB, HIV/AIDS, cardiac and
renal problems and diabetes mellitus were excluded. Patients receiving any medication other
than MDT were also excluded from the study.
Patients with ENL were treated according to the World Health Organization (WHO) treat-
ment guideline with steroids that initially consisted of 40 mg oral prednisolone daily and the
dose was tapered by 5 mg every fortnight for 24 weeks. All patients were given WHO-recom-
mended leprosy multidrug treatment (MDT). From each patient 10 mL venous blood sample
was obtained before treatment and after prednisolone treatment of patients with ENL reac-
tions. A fifteen day prednisolone treatment free period was used to obtain blood samples for
the after treatment sample [22, 23].
Serological response quantification by ELISA
The levels of anti ND-O-BSA (PGL-1), LAM and Ag85 antibodies were measured by
ELISA in the plasma samples of patients with ENL and LL controls before and after treat-
ment as previously described [24]. Recombinant protein Ag85, ND-O-BSA (PGL-1), and
LAM were coated onto high-affinity polystyrene flat-bottom 96-well ELISA plates (Dynex
Technologies, Chantilly, VA) using 50ng/well in 100μl buffer, pH 9.6 at 4˚C overnight.
Unbound antigen was washed away using PBS, pH 7.4, containing 1% Bovine serum
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albumin (BSA) and 0.05% Tween 80 (blocking buffer) six times. Serial 2-fold dilutions of
plasma samples from1:100 to 1:106 diluted in 100 μl blocking buffer were added to the
wells and incubated for 2 h at room temperature. After incubation with the primary anti-
body, the wells were washed six times as described above and followed by the addition of
100 μl of a 1:5,000 dilution of the secondary anti-human polyvalent antibody (Sigma) for
2 h. Following washing the wells with PBS six times, 100 μl of p-nitrophenylphosphate
substrate (Kirkegaard and Perry Labs, Gaithersburg, MD) was added. The absorbance at
405 nm was read using a VersaMax Pro plate reader (Molecular Devices, Sunnyvale, CA)
at 15min. BSA was used as negative control and all tested samples had an optical density
(OD) value less than 0.2 for BSA. An OD value above 1.5 was assigned as high response
for PGL-1 and LAM, and 1.0 for Ag85.
Lipid profile analysis
Serum levels of total cholesterol (TC), triglyceride (TG), high density lipoprotein (HDL) and
low density lipoprotein (LDL) were measured by the spectrophotometric method using a fully
automated clinical chemistry analyser Mindray BS-120 (Mindray, China) according to the rec-
ommendations of the manufacturers [25]. Analysis for serum samples for TC, TG, HDL and
LDL was carried out at the AHRI clinical laboratory. For external quality control 20 randomly
selected samples were analysed for total lipid profiles at ALERT clinical chemistry laboratory
using A25 Biosystem chemistry analyser (Oxford, UK). Total triglycerides were determined
using commercial reagents as described by [26]. Total high density lipoprotein and low density
lipoprotein levels were determined by enzymatic clearance method [27]. TC concentration
was estimated using the cholesterol oxidase/peroxidase method [28].
Statistical analysis
Lipid profiles. Unpaired t-test was used to compare the relative concentration of each
lipid profile in patients with ENL and LL controls. For comparing the lipid concentration in
patients with ENL before and after treatment, a paired t-test was used. Comparison between
acute and chronic ENL was made using unpaired t-test. Results are presented as mean ± stan-
dard error of the mean (SE) with a P-value cut-off of<0.05.
Antibody responses. Serological response data were analysed with two-tailed Mann-
Whitney U test using STATA 14 version 2 (San Diego California USA). Median estimator
with inter-quartile range was used for result presentation. For all data, graphs were produced
by GraphPad Prism version 5.01 for Windows (GraphPad Software, San Diego California
USA).
Results
Study patients’ clinical background
Thirty LL patients with ENL reaction (15 acute ENL and 15 chronic ENL) and 30 LL patient
controls without ENL reaction were recruited into the study. In patients with ENL, the male to
female ratio was 2:1; and patients had a median age of 27.5 [range: 18–56] years. In patients
with non-reactional LL controls, the male to female ratio was 3:1 with a median age of 25.0
[range: 18–60] years. None of the patients with ENL reactions had received prednisolone at
the time of enrolment to the study. At time of recruitment, 20 ENL patients were previously
untreated with MDT. After the first blood sample collection, ENL patients were immediately
started on regular treatment according to national and WHO guidelines.
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Prednisolone reduced antibody response to M. leprae PGL-1 antigen in
patients with ENL reactions
The concentration of anti-PGL-1 antibody was not significantly different in patients with
ENL and LL controls before treatment of ENL cases with prednisolone (Fig 1A). Similarly,
the levels of anti -LAM and anti-Ag85 antibody titres were not significantly different in
patients with ENL and LL controls before treatment (Fig 1B and 1C). However, after treat-
ment, patients with ENL had significantly lower anti-PGL-1 antibody titre than LL patient
controls (p < 0.0001). Similarly, anti -LAM and anti-Ag85 antibody titres were significantly
low in patients with ENL compared to LL controls after prednisolone treatment of ENL
cases (p < 0.0001) (Fig 1A–1C).
Comparison within ENL groups showed after prednisolone treatment of ENL the response
of plasma samples to PGL-1 antigen was significantly reduced (P = 0.01). On the other hand,
the response of plasma samples from ENL cases to LAM and Ag85 antigens did not change
after prednisolone treatment (Fig 2A–2C).
Patients with chronic ENL reactions had significantly low serum response
to M. leprae PGL-1 antigen
ENL patients were classified clinically into acute and chronic ENL. The serological responses
in serum samples from acute and chronic ENL were compared before and after prednisolone
Fig 1. Serological responses to antigens in patients with ENL compared to LL patient controls before and after prednisolone treatment of patients with
ENL reaction. (A): response to M. leprae PGL-1 antigen; (B): response to M. leprae Ag85 antigen; (C): response to M. leprae LAM antigen; Number of
ENL = LL = 25; Statistical test: Mann-Whitney unpaired test (U). ��� P�0.001; ���� P<0.0001. Error bars show median ± interquartile range.
https://doi.org/10.1371/journal.pntd.0007035.g001
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treatment of ENL cases. Serum samples from untreated acute ENL patients had significantly
higher responses (p<0.0001) to M. leprae PGL-1 antigen than serum samples from untreated
chronic ENL patients (Fig 3A). Although the response to PGL-1 was significantly reduced in
both groups after prednisolone treatment, the reduction was greater in chronic ENL (Fig 3A).
On the other hand, the serological response in serum samples from untreated acute and
chronic ENL patients to LAM antigens was not significantly different. The serum response to
LAM antigen did not change after prednisolone treatment in both acute and chronic ENL (Fig
3B). Response to Ag85 in untreated acute and chronic ENL patients was also not significantly
different. Similarly, after prednisolone treatment, the response to Ag85 did not change in
either acute or chronic ENL (Fig 3C).
Comparison within acute and chronic ENL cases before and after prednisolone treatment
showed that prednisolone treatment significantly reduced antibody response to PGL-1 in
patients with acute and chronic ENL. However, prednisolone greatly affected the serological
response to PGL-1 in chronic ENL cases compared to in acute ENL cases (Fig 4A). On the
other hand, prednisolone treatment did not affect serological response to LAM and Ag85 in
acute as well as chronic ENL cases (Fig 4B and 4C).
Fig 2. Serological responses to antigens in patients with ENL before and after prednisolone treatment (A): response to M. leprae PGL-1 antigen; (B): response
to M. leprae Ag85 antigen; (C): response to M. leprae LAM antigen; Number of ENL = LL = 25; Statistical test: Mann-Whitney unpaired test (U). � P�0.05;
Error bars show median ± interquartile range.
https://doi.org/10.1371/journal.pntd.0007035.g002
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Untreated patients with ENL reactions had low lipid profiles compared to
LL controls
We analysed the serum lipid profile in 30 patients with ENL cases and 30 LL patient controls
before and after prednisolone treatment of ENL cases. The levels of serum triglycerides were
low (99.95 ± 6.046 SE mg/dl) in patients with ENL reactions compared to LL patient controls
(158.7 ± 7.394 SE mg/dl) before treatment (P<0.0001) (Fig 5A). After prednisolone treatment
of ENL cases, the serum concentration of triglyceride was slightly increased in ENL patients to
110.8 ± 8.318 SE mg/d and reduced to 91.50 ± 5.876 SE mg/d in LL controls though the differ-
ence was not statistically significant (Fig 5B).
The concentration of serum low-density lipoprotein (LDL) in untreated patients with ENL
reactions was below half (34.05mg/dl ± 2.186SE) that of the corresponding concentration
(77.05mg/dl ± 4.225SE) in LL patient controls (P<0.0001) (Fig 5A). Interestingly, after treat-
ment, the concentration of LDL was significantly increased (50.52mg/dl ± 4.016SE) in patients
with ENL reactions while it was decreased by half (38.75mg/dl ± 3.910SE) in LL patient con-
trols (P = 0.0413) (Fig 5B).
Untreated ENL patients had lower serum total cholesterol (137.4mg/dl ± 7.210SE) than LL
controls (175.8mg/dl ± 8.805SE) (P = 0.0023). However, after treatment, the total cholesterol
concentration decreased to 126.2mg/dl ± 6.333SE and 120.7mg/dl ± 8.250SE in ENL patients
and LL controls respectively (Fig 5B). Similarly, untreated ENL patients had a significantly
Fig 3. Serological responses to antigens in patients with acute ENL (n = 15) compared with patients with chronic ENL (n = 15) before and after treatment.
(A): response to M. leprae PGL-1 antigen; (B): response to M. leprae Ag85 antigen; (C): response to M. leprae LAM antigen; Statistical test: Mann-Whitney
unpaired test (U). � P�0.05; �� P<0.005. Error bars show median ± interquartile range.
https://doi.org/10.1371/journal.pntd.0007035.g003
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lower serum concentration of high density lipoproteins (HDL) (9.20mg/dl ± 1.565SE) com-
pared to LL controls (29.76mg/dl ± 1.491SE) (P<0.0001). After treatment, in patients with
ENL reactions, the concentration of HDL was increased to 27.48mg/dl ± 1.822SE with the
Fig 4. Serological responses to antigens in patients with acute and chronic ENL before and after prednisolone treatment. (A): response to M. leprae PGL-1
antigen; (B): response to M. leprae LAM antigen; (C): response to M. leprae Ag85 antigen; Number of ENL = LL = 25; Statistical test: Mann-Whitney unpaired
test (U). � P�0.05; ���� P<0.0001. Scatter plots show median ± interquartile range.
https://doi.org/10.1371/journal.pntd.0007035.g004
Fig 5. Lipid profile of patients with ENL and LL controls before and after prednisolone treatment of ENL cases. (A): before treatment; (B): after treatment.
Number of ENL = LL = 30; Statistical test: unpaired t- test. � P�0.05; ��� P<0.001, ���� P<0.0001. Error bars show mean ± standard error of the mean.
TG = Triglycerides, TC = total cholesterol, LDL = low-density lipoprotein, HDL = high density lipoprotein.
https://doi.org/10.1371/journal.pntd.0007035.g005
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corresponding value of 32.58mg/dl ± 2.131SE in LL controls but the difference was not statisti-
cally significant (Fig 5B).
Prednisolone significantly increased low and high-density lipoproteins in
patients with ENL reactions
Comparison within ENL before and after prednisolone treatment has shown that prednisolone
treatment increased the mean serum LDL concentration from 34.05mg/dl ± 2.186SE to
50.52mg/dl ± 4.016SE in patients with ENL reactions and the difference was statistically signif-
icant (P = 0.0002). Similarly, the mean HDL concentration was significantly increased from
19.20mg/dl ± 1.565SE to 27.48mg/dl ± 1.822SE after prednisolone treatment of patients with
ENL reactions (P = 0.0014) (Fig 6).
On the other hand, although the mean serum concentration of triglycerides (TG) increased
from 99.95mg/dl ± 6.046SE to 110.8mg/dl ± 8.318SE after prednisolone treatment, this did not
reach statistical significance. Unlike the other lipid profiles, the mean serum concentration of
total cholesterol (TG) showed a decreasing tendency from 137.4mg/dl ± 7.210SE to 126.2mg/
dl ± 6.333 SE after prednisolone treatment although the difference was not statistically signifi-
cant (Fig 6).
Prednisolone alters serum concentration of triglycerides and low-density
lipoproteins in chronic ENL
The effects of prednisolone treatment on patients with acute and chronic ENL reactions were
compared before and after treatment. Untreated patients with acute ENL reactions had slightly
lower serum triglycerides concentrations (96.7mg/dl±7.918 SE) than untreated patients with
chronic ENL reactions (105.0 mg/dl± 10.65SE) and the difference was not statistically signifi-
cant (Fig 7A). However, after prednisolone treatment, in patients with chronic ENL reactions
Fig 6. Lipid profile within ENL before and after treatment. Number of ENL = 30; Statistical test: unpaired t- test. �� P<0.005, ��� P<0.001. Error bars
show mean ± standard error of the mean. TG = Triglycerides, TC = total cholesterol, LDL = low-density lipoprotein, HDL = high-density lipoprotein.
https://doi.org/10.1371/journal.pntd.0007035.g006
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the serum concentrations of TG was significantly increased to 120.8mg/dl ± 8.224SE and was
greater than in patients with acute ENL reactions (87.40mg/dl ± 6.496SE, (P = 0.0029) (Fig
7B). Untreated patients with acute ENL reactions had comparable serum LDL (37.20 mg/dl±
2.755SE and 36.15mg/dl ± 3.188E respectively) (Fig 7A). Interestingly, after prednisolone
treatment serum LDL was significantly increased in patients with chronic ENL reactions
(61.00mg/dl ± 4.855SE) compared with patients with acute ENL reactions (40.85mg/
dl ± 2.910SE, P = 0.001) (Fig 7B).
On the other hand, untreated patients with acute and chronic ENL reactions had similar
serum total cholesterol (130.4mg/dl ± 5.306SE and 152.8mg/dl ± 13.74SE respectively) (Fig
7A). After prednisolone, treatment the concentration of total cholesterol in patients with acute
ENL reactions (119.4mg/dl ± 7.741SE) and chronic ENL reactions (132.3mg/dl ± 4.754SE) was
not statistically significantly changed (Fig 7B). Similarly, untreated patients with chronic and
acute ENL reactions had 19.40mg/dl ± 1.538SE and 21.65mg/dl ± 2.811SE serum HDL con-
centrations respectively and the difference between the two groups was not statistically signifi-
cant. After prednisolone treatment, HDL concentration was increased to 28.15mg/dl ±
2.214SE in patients with acute ENL reactions and to 25.60mg/dl ± 1.177SE in patients with
chronic ENL reactions but the difference was not statistically significant (Fig 7B). Hence, pred-
nisolone increased serum triglycerides and low-density lipoprotein largely in patients with
chronic ENL reaction than in patients with acute ENL reactions.
We also compared the lipids concentration in acute and chronic ENL patients before and
after prednisolone treatment (Fig 8A–8D). Prednisolone treatment did not change the concen-
trations of triglycerides, total cholesterol and low-density lipoprotein in patients with acute
ENL. However, the concentration of high-density lipoprotein was significantly increased in
these patients after prednisolone treatment. On the other hand, prednisolone treatment signif-
icantly increased the concentrations of triglycerides, high and low density lipoprotein in
patients with chronic ENL (Fig 8A–8C and 8D).
Discussion
Serological response
Identification and characterization of M. leprae specific antigens is among the major goals to
be attained by researchers for accurate and reliable diagnosis of leprosy and leprosy reactions.
Fig 7. Lipid profiles before and after prednisolone treatment of acute ENL patients (n = 15) compared with chronic ENL patients (n = 15). (A): before
treatment; (B): after treatment.; Statistical test: unpaired t- test. �� P<0.005. Error bars show mean ± standard error of the mean. TG = Triglycerides, TC = total
cholesterol, LDL = low-density lipoprotein, HDL = high-density lipoprotein.
https://doi.org/10.1371/journal.pntd.0007035.g007
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The anti-PGL-1 antibody levels were not significantly different in patients with ENL
(OD = 1.430 ± 0.1281) and LL controls (1.341 ± 0.1415) (P>0.05) before treatment. However,
after treatment the level of anti-PGL-1 was significantly decreased (OD = 1.183 ± 0.1333) in
patients with ENL compared to LL patient controls (OD = 2.091 ± 0.1081) (p< 0.0001). A
study in Brazilian leprosy patients including 5 untreated ENL cases, 13 non- reactional LL
patients and 13 other clinical forms of leprosy had reported that the levels of anti-PGL-1 were
not significantly different in ENL and LL patients [29] which is in agreement with the present
result. The finding of lower level of anti-PGL-1 in ENL cases than in the corresponding LL
controls after prednisolone treatment of ENL patients in this study could be explained by the
effect of prednisolone treatment on immune response [30]. Previous studies have shown that
the level of anti-PGL-1 was significantly decreased in ENL patients treated with prednisolone
compared to LL patients [31].
When acute and chronic ENL cases were compared, acute ENL cases had higher levels of
anti-PGL-1 antibodies than chronic ENL cases before treatment (P�0.001). Similar findings
had been reported in an earlier study [32]. The differences in the levels of antibody response to
PGL-1 in acute and chronic cases could probably reflect the higher rate of PGL-1 synthesis in
acute ENL cases than in chronic ENL cases. PGL-1 is synthesised by viable and actively divid-
ing M. leprae [14, 33]. After treatment, the levels of antibody responses to PGL-1 still remain
lower in chronic ENL cases than in acute ENL cases and this could be due to the continue
effect of ongoing prednisolone treatment in patients with chronic ENL.
Fig 8. Lipid profiles before and after prednisolone treatment of acute and chronic ENL patients before and after prednisolone treatment. (A):
Triglycerides; (B): Total cholesterol; (C): low-density lipoprotein; (D): High-density lipoprotein; Number of ENL = LL = 30; Statistical test: unpaired t- test. ��
P<0.005; ���P<0.001. Box and whiskers show median ± interquartile range. TG = Triglycerides, TC = total cholesterol, LDL = low density lipoprotein,
HDL = high density lipoproteins.
https://doi.org/10.1371/journal.pntd.0007035.g008
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Similar to anti-PGL-1, the levels of anti-LAM serum antibodies were not significantly dif-
ferent in patients with ENL (OD = 1.191 ± 0.09790) and LL controls (OD = 1.116 ± 0.1183)
before treatment (P>0.05). However, after prednisolone treatment of ENL cases, the levels of
anti-LAM were lower in ENL cases (OD = 1.095 ± 0.08101) than in LL controls
(OD = 1.592 ± 0.08426) (P�0.0001). The reduction of the level of antibody response to LAM
in ENL cases after treatment could be due to the effect of prednisolone treatment as previously
reported [34]
Antigen 85 (Ag85) complex proteins are major secretory products of Mycobacterium. Like
for LAM, similar serum levels of anti-Ag85 antibodies were measured in the plasma samples
from patients with ENL (OD = 1.154 ± 0.1218) and LL controls (OD = 1.134 ± 0.1360). After
prednisolone treatment of ENL cases, the level of anti-Ag85 was lower in ENL cases (OD =
0.9713 ± 0.1164) than in in LL controls (OD = 1.536 ± 0.1108) (P�0.001). The differences in
the levels of antibody response to Ag85 after treatment in the two groups might be due to the
effect of prednisolone treatment of ENL cases. However, this assumption should be further
investigated and supported by definitive evidence.
Lipid profiles
Despite their beneficial effects, long-term use of corticosteroids is generally associated with
severe metabolic side effects including steroid-induced diabetes, muscle atrophy and disorders
in lipid metabolism which limit their therapeutic usefulness [35]. Studies have shown that lipid
concentrations are altered in leprosy across the spectrum and some researchers suggested the
alteration in the lipid profile could be useful as a diagnostic tool for leprosy [36]. We have
shown that untreated patients with ENL had lower TG, LDL and HDL than non-reactional LL
patient controls (P�0.05). It has been shown that infection and inflammation are both associ-
ated with marked changes in lipid and lipoprotein metabolism. In addition to lipid transport,
lipoproteins participate in innate immunity[37].Therefore, the findings of decreased serum
lipid and lipoproteins in patients with ENL reactions could be due to the utilization of various
types of lipids and lipoproteins in the process of inflammation as these patients are suffering
from inflammatory complication of leprosy. Triglycerides are a major component of very-low-
density lipoproteins (VLDL) and serve as a source of energy. During inflammation, TG pro-
vide lipid substrates for the activated immune system [37]. Cholesterol may also be used for
lymphocyte activation and proliferation. Furthermore, infection is often associated with cellu-
lar injury and areas of injury may need extra cholesterol for new membrane synthesis [38].
Following prednisolone treatment of ENL cases, serum lipid levels increased significantly.
The serum concentration of TG, TC and HDL in treated ENL was comparable with the corre-
sponding values obtained for LL controls. However, LDL was significantly increased in
patients with ENL reactions after they were treated with prednisolone compared to LL con-
trols. Studies have shown that prednisolone leads to an adverse lipid profile with increased TC
and LDL levels [19]. The significant increase of LDL in patients with ENL reactions after treat-
ment with prednisolone would predict the possibility of prednisolone-induced complications
in these patients although it needs further investigation.
Comparison within ENL groups before and after prednisolone treatment has shown that
prednisolone treatment significantly increased the mean serum LDL concentration from
34.05mg/dl ± 2.186SE to 50.52mg/dl ± 4.016SE in patients with ENL reactions. Likewise, the
mean HDL concentration was significantly increased from 19.20mg/dl ± 1.565SE to 27.48mg/
dl ± 1.822SE after prednisolone treatment of patients with ENL reactions. Although predniso-
lone mediated adverse plasma lipid profiles are well documented, the mechanisms behind
such changes are still not clear. Plasma cholesterol level is mainly regulated in the liver. The
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hepatic low-density lipoprotein receptor (LDLR), which contributes up to 80% of LDL clear-
ance from the plasma in various animal species, affects both the rates of formation and clear-
ance of LDL[39]. In vitro and in vivo studies have shown that prednisolone-mediated
decreases in hepatic LDLR mRNA and activity, resulting in decreased binding and degradation
of LDL in both humans and rats [39, 40]. Hence, the finding of increased serum concentration
of LDL and HDL in patients with ENL reaction after prednisolone treatment shows the poten-
tial risk of prednisolone for LDL/HDL induced complications such as cardiovascular and
hepatic complications.
We also analysed the lipid profile data to see the effect of prednisolone in patients with
acute and chronic ENL. Interestingly our data show that prednisolone significantly alters
serum concentration of triglycerides and low-density lipoproteins more so in chronic ENL
than in patients with acute ENL. In patients with chronic ENL reactions, serum concentration
of TG was significantly increased to 120.8mg/dl ± 8.224SE compared to patients with acute
ENL reactions (87.40mg/dl ±6.496SE). Similarly, after prednisolone treatment, serum LDL
was significantly increased in patients with chronic ENL reactions (61.00mg/dl ± 4.855SE)
compared with patients with acute ENL reactions (40.85mg/dl ± 2.910SE). These differences
in TG and LDL could be explained by the fact that patients with chronic ENL reaction receive
more prednisolone for extended periods than patients with acute ENL.
Conclusion
In conclusion, the significantly increased prednisolone-induced LDL and TG levels, particu-
larly in patients with chronic ENL reactions calls for great caution when prednisolone is used
for treatment of ENL reactions. However, to describe the long-term impact of prednisolone
treatment on the lipid profiles of ENL patients we did not follow the patients after they com-
pleted their treatment. Hence, our finding does not account for whether prednisolone treat-
ment causes temporary or permeant lipid profiles alteration in ENL patients. We recommend
that lipid levels should be monitored and managed in patients with both acute and chronic
ENL to minimize the long-term risk of prednisolone-induced complications. We also recom-
mend that future research should focus on developing alternative and safe treatment options
for ENL reaction.
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